v3.25.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
OPERATING EXPENSES    
General and administrative expenses $ 3,088,671 $ 1,340,168
Total operating expenses (3,088,671) (1,340,168)
Other income (expense):    
Change in fair value of subscription loan (9,105,853)
Interest expense – debt discount (891,624) (8,966)
Interest earned on investments held in Trust Account 548,676 5,813,213
Total other income, net (9,448,801) 5,804,247
Net (loss) income (12,537,472) 4,464,079
Aspire Biopharma Inc [Member]    
REVENUE    
Gross Receipts
Net Revenue
COST OF REVENUE    
Cost of goods sold
Total cost of revenue
GROSS PROFIT
OPERATING EXPENSES    
General and administrative expenses 940,421 246,895
Research and development 144,356 72,050
Marketing and sales 126,094 39,644
Total operating expenses 1,210,871 358,589
Other income (expense):    
Interest expense – debt discount (97,988)
Total other income, net (97,988)
Net gain/(loss) before income tax provision (1,308,859) (358,589)
Provision for Income Taxes 1,013 481
Net (loss) income $ (1,309,872) $ (359,070)
Weighted average number of shares outstanding - basic 507,353,659 481,794,521
Weighted average number of shares outstanding - diluted 507,353,659 481,794,521
Loss per share - basic $ (0.003) $ (0.001)
Loss per share - diluted $ (0.003) $ (0.001)
Common Class A [Member]    
Other income (expense):    
Weighted average number of shares outstanding - basic 8,244,188 16,461,668
Weighted average number of shares outstanding - diluted 8,244,188 16,461,668
Loss per share - basic $ (1.52) $ 0.23
Loss per share - diluted $ (1.52) $ 0.23
Common Class B [Member]    
Other income (expense):    
Weighted average number of shares outstanding - basic 2,717,466
Weighted average number of shares outstanding - diluted 2,717,466
Loss per share - basic $ 0.23
Loss per share - diluted $ 0.23